article Open AccessTop 1% cited
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
Clinical Cancer Research · 2014 · Vol. 20(19) · pp. 5064–5074
Janis M. Taube✉Alison Klein(Johns Hopkins University)Julie R. BrahmerHaiying XuXiaoyu PanJung Ho KimLieping Chen(Yale University)Drew M. PardollSuzanne L. Topalian✉(Johns Hopkins University)Robert A. Anders
Abstract
Tumor PD-L1 expression reflects an immune-active microenvironment and, while associated other immunosuppressive molecules, including PD-1 and PD-L2, is the single factor most closely correlated with response to anti-PD-1 blockade. Clin Cancer Res; 20(19); 5064-74. ©2014 AACR.
Cancer Immunotherapy and BiomarkersImmune Cell Function and InteractionImmunotherapy and Immune ResponsesImmune systemTumor microenvironmentNivolumabMedicineMelanomaRenal cell carcinomaLung cancerCytotoxic T cellTumor-infiltrating lymphocytesImmunotherapy
MeSH terms
NivolumabAntibodies, MonoclonalAntineoplastic AgentsBiopsyHumansNeoplasm MetastasisNeoplasm StagingNeoplasmsGene ExpressionLymphocytes, Tumor-InfiltratingTreatment OutcomeMolecular Targeted TherapyTumor MicroenvironmentB7-H1 AntigenProgrammed Cell Death 1 Receptor
Funding
- American Association for Cancer Research
- Johns Hopkins University
- Jounce Therapeutics
Citations
2,320
FWCI
121.84
field-weighted impact
References
45
Percentile
100%
vs. same field & year
Citations per year
Cited by
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Science Translational Medicine · 2016 · 2,413 citations
Prognostic and predictive value of PDL1 expression in breast cancer
Oncotarget · 2014 · 496 citations
Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
Oncotarget · 2016 · 418 citations
Immune Checkpoint Blockade in Cancer Therapy
Journal of Clinical Oncology · 2015 · 2,706 citations
Classifying Cancers Based on T-cell Infiltration and PD-L1
Cancer Research · 2015 · 1,441 citations
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Oncotarget · 2017 · 415 citations
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Journal of Clinical Oncology · 2019 · 2,871 citations
References
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Nature Medicine · 1999 · 2,463 citations
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology · 2010 · 2,913 citations
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Nature Medicine · 2002 · 4,970 citations
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Immunity · 1999 · 2,706 citations
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Science Translational Medicine · 2012 · 2,123 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
New England Journal of Medicine · 2012 · 7,941 citations
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Nature Immunology · 2001 · 2,931 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.
